Beyond first-line systemic treatment in oesophagogastric cancer
Research type
Research Study
Full title
Beyond first-line systemic treatment in metastatic oesophagogastric cancer
IRAS ID
270761
Contact name
Willemieke P.M. Dijksterhuis
Contact email
Sponsor organisation
Netherlands Comprehensive Cancer Organisation (IKNL)
Duration of Study in the UK
0 years, 8 months, 30 days
Research summary
The aim of this project is to explore the use of beyond first-line palliative systemic treatment (chemotherapy and targeted therapy) in metastatic oesophagogastric cancer in clinical practice. Nearly all oesophagogastric cancer patients experience disease progression on the first administered (first-line) systemic therapy, which results in discontinuation of this treatment. Currently, evidence on real-world use of treatments after progression on this first-line chemotherapy, and outcomes in oesophagogastric cancer patients are lacking, but could provide valuable information alongside the (scarce) results of clinical trials. For this study, we would like to use nationwide, multicentre data of British and Dutch patients which has been collected by the National Cancer Registration and Analyses Service (NCRAS) and the Netherlands Cancer Registry (NCR), respectively.
Retrospective data of oesophagogastric cancer patients diagnosed with metastases between 2010 and 2018 that were treated with chemotherapy and/or targeted therapy, will be included. Analyses will be performed at the NCRAS in London, UK.
We hypothesize that a wide variety of beyond-first line systemic regimens is used, because the optimal beyond first-line treatment regimens have not been identified, and because a large heterogeneity has been found in first-line systemic treatment as well. We expect the administration and type of beyond first-line treatment to be associated with the type of first-line systemic therapy regimen, and with the number of treated patients per hospital.
We will analyse pooled data of all British and Dutch oesophagogastric cancer patient, as well as for both countries separately. By comparing the British and Dutch data, we would like to look at differences in characteristics and outcomes of patients receiving beyond first-line treatment. Moreover, we would like to explore and compare variation in the administration of beyond first-line treatment in both countries.
This study will be conducted from January 2019 to June 2020.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
20/NW/0086
Date of REC Opinion
20 Feb 2020
REC opinion
Favourable Opinion